Uncategorized
Mazdutide (GLP-1/GCGR Dual Agonist): The Next-Generation Metabolic Peptide Guide
Mazdutide (GLP-1/GCGR Dual Agonist): The Next-Generation Metabolic Peptide Guide
Mazdutide is a once-weekly dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (GCGR), developed for obesity and metabolic dysfunction. By combining GLP-1’s appetite suppression with glucagon’s energy expenditure effects, mazdutide represents a distinct mechanism among next-generation metabolic peptides. This guide reviews its mechanism, evidence, applications, dosing, and safety.
1. What Is Mazdutide?
Mazdutide (also known as IBI362) is a synthetic peptide engineered with balanced GLP-1R and GCGR agonism. Unlike GLP-1-only agonists, the added glucagon activity targets energy expenditure and hepatic metabolism, aiming for greater weight loss and metabolic benefits. It is among the most advanced dual agonists in clinical development.
- Compound type: GLP-1/GCGR dual receptor agonist (peptide)
- Other name: IBI362
- Administration: Once-weekly subcutaneous injection
- Core mechanism: GLP-1 (appetite) + glucagon (energy expenditure)
- Status: Investigational drug; research compound
2. Mechanism of Action
Mazdutide combines two complementary metabolic pathways:
- GLP-1 receptor agonism: Suppresses appetite, slows gastric emptying, and improves glycemic control
- Glucagon receptor agonism: Increases energy expenditure and hepatic glucose output regulation
- Weight loss synergy: Dual mechanisms produce additive effects on fat mass reduction
- Hepatic effects: Studied for liver fat reduction in metabolic dysfunction-associated steatotic liver disease
3. The Research Landscape
| Research area | Reported findings |
|---|---|
| Obesity | Significant weight reductions in phase 2 trials, dose-dependent |
| Type 2 diabetes | Improved glycemic control and HbA1c reduction in clinical studies |
| Liver fat | Reductions in hepatic fat content reported in MASLD/MASH studies |
| Tolerability | GI events consistent with GLP-1 class, mostly mild-moderate |
Mazdutide’s dual-agonist profile positions it alongside retatrutide (triple agonist) and cagrilintide combinations in the next wave of metabolic peptides.
4. Research Applications
- Obesity research: Weight management protocols with body composition endpoints
- Metabolic dysfunction research: T2D, insulin resistance, and metabolic syndrome models
- Liver research: Hepatic steatosis and MASLD/MASH intervention studies
- Energy expenditure research: Glucagon-mediated thermogenesis and fat oxidation
For comparison with other incretin peptides, see our retatrutide guide and GLP-1 peptide comparison guide.
5. Dosing and Protocol Notes
- Trial doses: 1.5-6 mg once weekly, with titration to minimize GI effects
- Administration: Subcutaneous injection, typically abdomen or thigh
- Reconstitution: If using lyophilized research forms, use bacteriostatic water; see our reconstitution and dosage guide
- Titration: Gradual dose escalation is standard in clinical protocols
6. Side Effects and Considerations
- Gastrointestinal events: Nausea, diarrhea, and vomiting — dose-dependent and common
- Appetite suppression: Marked fullness or reduced intake expected
- Glucagon-mediated effects: Possible effects on glucose dynamics requiring monitoring
- Contraindications: Pregnancy, lactation, and personal/family history of medullary thyroid carcinoma
7. Frequently Asked Questions
How does mazdutide differ from semaglutide? Semaglutide is GLP-1-only; mazdutide adds glucagon receptor agonism for additional energy expenditure effects.
Is mazdutide similar to retatrutide? Retatrutide is a triple agonist (GLP-1/GIP/glucagon); mazdutide is a dual agonist (GLP-1/glucagon).
Is mazdutide approved? It is investigational, with phase 3 trials in progress in major markets.
Related Reading
- Retatrutide Research Guide
- GLP-1 Peptide Comparison Guide
- Cagrilintide (Amylin Analog) Guide
- Semaglutide Research Guide
Shop Related Research Compounds
Browse our research catalog, including Mazdutide, Retatrutide, and Tirzepatide, all supplied with batch COAs.
Disclaimer: This article is for educational and research purposes only. Mazdutide is an investigational compound not approved for general human use. Always consult qualified professionals regarding research protocols.
